MedTrace Logo

A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic Pain

NCT00375960 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2007-04-02

No results posted yet for this study

Summary

The objective of this study is to investigate the safety and efficacy of an investigational drug, V3381, for the treatment of diabetic peripheral neuropathic (DPN) pain (pain in one's feet and legs, or even in one's hands and arms, sometimes experienced by people with diabetes). An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA) and/or Health Canada.

Conditions

  • Pain
  • Diabetic Neuropathies

Interventions

DRUG

V3381

DRUG

Placebo

Sponsors & Collaborators

  • Cita NeuroPharmaceuticals

    collaborator INDUSTRY

  • Vernalis (R&D) Ltd

    lead INDUSTRY

Principal Investigators

  • Christine Sang, M.D., MPH · Brigham and Women's Hospital, Harvard Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Completion
2007-04-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00375960 on ClinicalTrials.gov